

THOMPSON COBURN

RECEIVED
CENTRAL FAX CENTER
AUG 11 2005

*Thompson Coburn LLP
Attorneys at Law*
One US Bank Plaza
St. Louis, Missouri 63101-1693
314-552-6000
FAX 314-552-7000
www.thompsoncoburn.com

Facsimile
FOR IMMEDIATE DELIVERY

To	Firm Name	Phone	Fax
Examiner Henley	U.S. Patent & Trademark Office		571-273-0575
U.S. Patent & Trademark Office			571-273-8300

From: Charles P. Romano, Senior Patent Agent
cap
 Date: 08/11/2005
 Message:

Atty/Client/Matter No.: 3647/53047/31628

Total Number of Pages, including this page: 15

If you do not receive all of the pages, please call 314-552-6255 as soon as possible.

Thank you,
 Fax Department - Operator: *LLP* Time of Transmittal: 9:44 A.M./P.M.

Confidentiality Note

The information contained in this facsimile transmission is legally privileged and confidential information intended only for the use of the individual or entity named above. If the reader of this transmission is not the intended recipient, you are hereby notified that any dissemination, distribution, or copying of this transmission is strictly prohibited. If you have received this transmission in error, please immediately notify us by collect telephone call and return the original transmission to us at the above address by U.S. mail. Thank you.

RECEIVED
CENTRAL FAX CENTER
AUG 11 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:	Dugan et al.	Group No.:	1614
Serial No.:	10/083,283	Atty. Docket No.:	53047-31628
Filed:	February 23, 2002		
For:	<i>Carboxyfullerenes and Methods of Use Thereof</i>	Examiner:	Henley III, Raymond J..

DECLARATION OF DR. LAURA L. DUGAN

UNDER 37 C.F.R. §1.132

I, Dr. Laura L. Dugan, declare and state as follows:

1. All of the statements made herein of my own knowledge are true and all statements made on information and belief are believed to be true.
2. I am the first-named inventor of U.S. Patent Application No. 10/083,283 for Carboxyfullerenes and Methods of Use Thereof filed February 23, 2002 ("Patent Application"). I am also a co-inventor on U.S. Patent 6,265,443 for Methods of Treating Neuronal Injury with Carboxyfullerene (Choi et al.).
3. My current position is Professor, Larry L. Hillblom Chair in Geriatric Medicine in the Division of General Medicine and Geriatrics at the Department of Medicine, University of California, San Diego.

3094240

4. The Patent Application incorporates in it's entirety U.S. Patent 6,265,443 for Methods of Treating Neuronal Injury with Carboxyfullerene (Choi et al). Choi et al shows that $C_{60}(C(COOH)_2)_3$ compounds are effective free radical scavengers (i.e. can eliminate superoxide radicals) and can reduce neuronal cell death in cultured cells treated with AMPA or NMDA. Choi et al also correctly states that other water soluble $C_{60}(C(COOH)_2)_n$ compounds with n=1 or n=2 are effective free radical scavengers.

5. Prior to the February 23, 2002 filing date of the Patent Application, I demonstrated that the carboxyfullerene derivatives "C₃" ($C_{60}(C(COOH)_2)_3$; malonic acid groups at the e,e,e positions), "Penta-1,2" (two stereoisomers of $C_{60}(C(COOH)_2)_2(C(CHCOOH))$; groups at the e,e,e positions), "Tetra's" (four stereoisomers of $C_{60}(C(COOH)_2)(C(CHCOOH))_2$; groups at the e,e,e positions), and "C₃-lite" (four isomers of $C_{60}(C(CHCOOH))_3$; groups are in the e,e,e positions) exhibited comparable superoxide dismutase SOD activity (Exhibit A1 to A3). The demonstration of superoxide dismutase activity of the "C₃", "Penta", "Tetra's" and "C₃-lite" derivatives of carboxyfullerene was accomplished using methods that are fully disclosed in the Patent Application. The "C₃", "Penta", and "C₃-lite" derivatives of carboxyfullerene were also shown to reduce NMDA receptor toxicity, a form of neuronal cell death mediated by mitochondrial superoxide production (Exhibit A4 to A11) prior to the February 23, 2002 filing date of the Patent Application. The demonstration of reduced NMDA receptor toxicity of neuronal cells by the "C₃", "Penta", "Tetra's" and "C₃-lite" derivatives of carboxyfullerene was accomplished using methods that are fully disclosed in the Patent Application, which incorporates by reference US Patent No. 6,265,443 to Choi et al. Since the carboxyfullerene derivatives "C₃", "Penta", "Tetras" and "C₃-lite" all exhibited SOD activity, since "C₃", "Penta", and "C₃-lite" all reduced NMDA receptor toxicity, and since "C₃" was shown in the Patent Application to increase lifespan when administered to mice, one skilled in the art would have expected that all of these carboxyfullerene derivatives would also have had similar lifespan-extending capabilities as "C₃" at comparable *in vivo* doses. It is therefore my belief that additional carboxyfullerene derivatives other than "C₃" could have been used at the time of February 23, 2002 filing date of the Patent Application to obtain lifespan increases.

5. I further declare that all statements herein made by my own knowledge are true and all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the above-identified application.



Dr. Laura L. Dugan

July 12, 2005